StocksMedium•5 November 2026•
1 min read
Daewoong Pharmaceutical Q3 Profit Jumps 43.5% on Record Nabota Exports
Key Facts
1Daewoong Pharmaceutical's Q3 operating profit rose 43.5% to 76.8 billion won.
2Nabota exports reached a quarterly record of 106.8 billion won, up 127.9% year-on-year.
Daewoong Pharmaceutical's operating profit rose 43.5% to 76.8 billion won in the third quarter of 2026. Seoul Economic Daily reported that the company's revenue increased 17.1% to 415.8 billion won during the period, driven by robust performance in its export division.
Exports of Nabota, the company's botulinum toxin product, reached a quarterly record of 106.8 billion won, marking a 127.9% increase year-on-year. This growth helped expand the operating margin to 18.5%, while net profit rose 9.9% to 47.3 billion won according to preliminary regulatory filings released on November 4, 2026.